Novel Radioligand Therapy Proven Superior for Metastatic Prostate Cancer Patients
SNMMI Value Initiative – March 9, 2022
A novel prostate cancer treatment — 225Ac-PSMA-617 radioligand therapy — has been shown to increase the progression free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) patients, according to research published by The Journal of Nuclear medicine. Mike Sathekge, professor and head of the Nuclear medicine Department at the University of Pretoria and Steve Biko Academic Hospital in Pretoria, South Africa, explains his study.